Drugs / Dexamethasone Palmitate
Dexamethasone Palmitate
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00665106 | Apr 2008 → Sep 2011 | diabetic macular edema | Santen SAS | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05693467 | Mar → Jun 2023 | — | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07341854 | Jun 2026 → Jun 2027 expected | neuropathy, painful | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07344246 | Feb 2026 → Sep 2028 expected | herpes zoster | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06997419 | Jul 2025 → Nov 2026 expected | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT06988124 | Jun 2025 → May 2027 expected | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT06981754 | Jun 2025 → Apr 2026 | — | Beijing Tiantan Hospital | Completed | No outcome recorded |
| — | NCT05920967 | Jul 2023 → Sep 2024 | chronic pain syndrome | Xijing Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dexamethasone Palmitate | “Dexamethasone Palmitate (DXP) is a lipophilic prodrug of dexamethasone with unique pharmacological properties.” NCT07344246 ↗ |
| Known as | D-PAL | “Participants will be randomised in a 1:1 ratio to dexamethasone palmitate (D-PAL) emulsion group and dexamethasone (DSP) group.” PMID 39819928 ↗ Jan 2025 |
| Known as | DXP | “The participants in the dexamethasone palmitate (DXP) group will receive a single paravertebral space infusion of 21 ml of the first dose of analgesia, consisting of 0.5...” NCT05920967 ↗2“Dexamethasone Palmitate (DXP) is a lipophilic prodrug of dexamethasone with unique pharmacological properties.” NCT07344246 ↗ “Dexamethasone palmitate (DXP) emulsion is a targeted liposteroid.” PMID 37225277 ↗ May 2023 |
| Known as | NOVA63035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00665106 ↗ |
| Modality | Other / unclassified | “NOVA63035 "Corticosteroid"” NCT00665106 ↗ |
| Route | Other | “local incision site infiltration with ropivacaine plus DXP” PMID 37225277 ↗ May 2023 |